Results 11 to 20 of about 71,664 (187)

Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC) [PDF]

, 2005
Background: The aim of this retrospective analysis was to evaluate the impact of trastuzumab-based regimens on the survival of patients with HER2-overexpressing metastatic breast cancer (MBC).
Heinrich, B., Stemmler, H. J., Kahlert, S., Heinemann, Volker, Siekiera, W., Untch, M.   +5 more
core   +1 more source

Trastuzumab (Herceptin (R)): Monoclonal antibody in the treatment of HER2/neu-overexpressing breast cancer in the metastatic and (neo)adjuvant situation [PDF]

, 2006
Trastuzumab (Herceptin (R)) is a humanized monoclonal antibody that specifically targets HER2/neu (human epidermal growth factor receptor-2) breast cancer cells, which are overexpressed in about 25-30% of breast carcinomas.
Bauerfeind, Ingo, Rückert, Sandra, Lenhard, Miriam, Ditsch, Nina, Kümper, Carolin, Kahlert, Steffen, Friese, Klaus, Untch, Michael   +7 more
core   +1 more source

Sprouty 2 is an independent prognostic factor in breast cancer and may be useful in stratifying patients for trastuzumab therapy [PDF]

, 2011
Background: Resistance to trastuzumab is a clinical problem, partly due to overriding activation of MAPK/PI3K signalling. Sprouty-family proteins are negative regulators of MAPK/PI3K signalling, but their role in HER2-therapy resistance is unknown ...
Faratian Dana, Sims, Andrew H., Sims Andrew H., Simon P. Langdon, Langdon, Simon P., Kay Charlene, Dana Faratian, Charlene Kay, Um InHwa, Harrison David J., David J. Harrison, Um, Inhwa, Simon P Langdon, David J Harrison, Langdon Simon P., Faratian, Dana, Mullen, Peter, Andrew H. Sims, Kay, Charlene, Kay, Charlene; id_orcid, Mullen Peter, Andrew H Sims, Peter Mullen, Harrison, David J., Inhwa Um   +24 more
core   +1 more source

Phase Ib study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis

Hepatology, EarlyView., 2022
Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed death‐ligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou, Yongkun Sun, Wen Zhang, Jiajia Yuan, Zhi Peng, Wei Wang, Jifang Gong, Lin Yang, Yanshuo Cao, Hong Zhao, Chao Chen, Weifeng Wang, Lin Shen, Aiping Zhou   +13 more
wiley   +1 more source

HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer [PDF]

, 2013
Introduction: Recent data suggest that benefit from trastuzumab and chemotherapy might be related to expression of HER2 and estrogen receptor (ESR1). Therefore, we investigated HER2 and ESR1 mRNA levels in core biopsies of HER2-positive breast carcinomas
Jens Huober, Reinisch, Mattea, Sibylle Loibl, Silvia Darb-Esfahani, Michael Untch, Hans Tesch, Martin-Leo Hansmann, Jan C Brase, Knut Engels, Judith Prinzler, Keyur Mehta, Minckwitz, Gunter von, Brase, Jan C., Kronenwett, Ralf, Hansmann, Martin-Leo, Huober, Jens, Engels, Knut, Solbach, Christine, Tesch, Hans, Carsten Denkert, Denkert, Carsten, Gunter von Minckwitz, Bruno V Sinn, Loibl, Sibylle, Mattea Reinisch, Peter A Fasching, Sinn, Bruno V., Ralf Kronenwett, Christine Solbach, Prinzler, Judith, Mehta, Keyur, Fasching, Peter Andreas, Untch, Michael, Denkert, Carsten Michael, Darb-Esfahani, Silvia   +34 more
core   +2 more sources

Re-evaluation of HER2 status in metastatic breast cancer and tumor-marker guided therapy with vinorelbine and trastuzumab [PDF]

, 2005
Background: HER2 is overexpressed in 20 - 30% of breast cancers. Compared to chemotherapy alone, chemotherapy with trastuzumab improves clinical outcome in patients with HER2- positive metastatic breast cancer ( MBC). In general, HER2 status in a primary
Lässig, D., Stemmler, H. J., Stieber, P., Heinemann, Volker   +3 more
core   +1 more source

Long‐term prognosis is associated with residual disease after neoadjuvant systemic therapy but not with initial nodal status

BJS (British Journal of Surgery), EarlyView., 2020
This long‐term follow‐up study determined survival rates in a Swedish national cohort of 417 patients with breast cancer who all had neoadjuvant systemic therapy (NAST). Sentinel lymph node biopsy (SLNB) was performed before NAST in clinically node‐negative and after NAST in clinically node‐positive patients.
L. Zetterlund, F. Celebioglu, T. Hatschek, J. Frisell, J. de Boniface   +4 more
wiley   +1 more source

Generation and in vitro evaluation of TH-Trastuzumab-MCC-ODN conjugate.

, 2023
(A) SDS-PAGE analysis of TH-Trastuzumab in native, reduced and reoxidated form on 4–20% gel stained with SimplyBlue. (B) SDS-PAGE analysis of TH-Trastuzumab-MCC-CpG conjugates under non-reducing conditions. The gel was sequentially stained with SYBR Gold
Kam Zaki (8907518), Diana Corogeanu (14784300), Sandra S. Diebold (14784303), James N. Arnold (2217103), Andrew J. Beavil (222849)   +4 more
core   +1 more source

Therapeutic targeting of Integrin v 6 in breast cancer [PDF]

, 2014
BACKGROUND: Integrin ?v?6 promotes migration, invasion, and survival of cancer cells; however, the relevance and role of ?v?6 has yet to be elucidated in breast cancer.METHODS: Protein expression of integrin subunit beta6 (?6) was measured in breast ...
Thomas, GJ, Louise Jones, J., Eccles, D, Hart, I. R. (Ian R.), Kendrew, Jane, Chou, Patrick, Gillett, C., Jordan, L, Violette, S., Brentnall, A., Duffy, S.W., Warwick, J., Thomas, Gareth J., Saha, A, Hart, I.R., Bowen, R, Barry, S.T., Green, Andrew R, Gillett, Cheryl, Vallath, S, Bowen, R., Haider, Syed, Barry, Simon T, Moore, K.M., Hart, Ian R., Barry, Simon T., Gabe, R., Haider, S., Chelala, C, Jones, J.L., Thomas, Gareth J, Chelala, C., Eccles, Diana, Ellis, Ian O, Kendrew, J., Green, Andrew R., Weinreb, PH, Jones, JL, Chou, P, Vallath, S., Marshall, John F., Jordan, L., Brouilette, Kellie, Kendrew, J, Duffy, Stephen W, Ellis, I.O., Quinlan, P., Quinlan, P, Gabe, R, Haider, S, Moore, Kate M, Jordan, Lee, Hart, Ian R, Marshall, J.F., Brentnall, Adam, Moore, KM, Jones, J. Louise, Barry, ST, Gillett, C, Warwick, J, Thompson, Alastair M, Weinreb, Paul H, Vallath, Sabari, Chou, P., Green, AR, Thompson, A.M., Thompson, AM, Saha, Antonio, Violette, Sheila, Tapper, W.J., Hart, IR, Ellis, IO, Jones, J Louise, Tapper, William J., Brentnall, A, Weinreb, P.H., Brouilette, K., Tapper, Will, Gabe, Rhian, Thompson, Alastair M., Saha, A., Eccles, D., Violette, Shelia, Tapper, William J, Marshall, JF, Thomas, G J., Weinreb, Paul H., Duffy, Stephen W., Moore, Kate M., Brouilette, K, Green, A.R., Quinlan, Phillip, Duffy, SW, Ellis, Ian, Warwick, Jane, Marshall, John F, Bowen, Rebecca, Chelala, Claude, Tapper, WJ, Violette, S, Ellis, Ian O.   +100 more
core   +1 more source

Systems analysis of drug-induced receptor tyrosine kinase reprogramming following targeted mono- and combination anti-cancer therapy [PDF]

, 2014
The receptor tyrosine kinases (RTKs) are key drivers of cancer progression and targets for drug therapy. A major challenge in anti-RTK treatment is the dependence of drug effectiveness on co-expression of multiple RTKs which defines resistance to single ...
Goltsov, Alexey, Stylianos Kyriakidis, Hilal Khalil, Simon P. Langdon, Harrison, David James, Langdon, Simon P., Bown, James L., Khalil, Hilal S., Simon Langdon, Tero Soininen, Khalil, Hilal S, Soininen, Tero, Alexey Goltsov, Huizhong Hu, David J. Harrison, Bown, James, David Harrison, Deeni, Yusuf, Harrison, David J, Kyriakidis, Stylianos, Hu, Huizhong, Deeni, Yusuf Y.; id_orcid, Yusuf Deeni, Hilal S. Khalil, Langdon, Simon P, James Bown, Harrison, David J.   +26 more
core   +1 more source